Update your tester profile Login
  • COVID-19 Prism Update

    Updated on April 1, 2020

    It’s hard to escape news about COVID-19. And with good reason. As an organisation on the front line of finding vaccines for diseases such as Coronavirus, our number one priority is the health and safety of our staff, our clinical trial participants, and the broader community.

    We have answered some of the most frequently asked questions below. If you have any other questions, please get in touch with us at 651-641-2900.

    Is there any impact from Coronavirus (COVID-19) on clinical trials at Nucleus Network sites (Centre for Clinical Studies, Q-Pharm or Prism)?

    Nucleus Network is committed to continuing the vital work undertaken by our clinical trials, with studies continuing to take place.

    While Coronavirus (COVID-19) infection rates in Melbourne, Brisbane and Minnesota remain low, the safety and quality of our trials and facilities is our number one priority. We have introduced strict measures to ensure the safety of all clinical trial participants, visitors and staff, and the quality of our trials.

    In addition to the standard infection control practiced in its three clinics, Nucleus Network has implemented increased risk mitigations associated with Coronavirus (COVID-19). These include:

    • Coronavirus (COVID-19) participant / patient screenings on phone and in-clinic,
    • Regular hand sanitizing using alcohol-based hand rub with 70% alcohol,
    • Every second bed practice to surpass ‘social distancing’ requirements,
    • 6 feet spacing in waiting, dining and recreational areas,
    • Personal Protective Equipment (PPE),  are worn by medical officers, nursing and clinical staff during all participant interactions requiring close physical interaction.
    • Isolation protocols are in place where additional PPE, including goggles, gowns and masks, are worn as appropriate when required for any person displaying high risk symptoms, this includes utilizing dedicated bed and bathroom bays
    • Infection prevention and control procedures in line with World Health Organisation (WHO) and best practice guidelines.

     

     

    These measures go above and beyond recommended clinical practices and provide a gold standard in infection control. We will continue to update and refine its approach to Coronavirus (COVID-19) as more information about the virus continues to be learned.

    Can I still participate in a Nucleus Network clinical trial?

    Yes. We are still recruiting for clinical trials however have implemented an age restriction on participants of 18-59 years (inclusive) to protect older members of our community. We are currently only allowing volunteers from the Minneapolis/St. Paul area.

    The risk of Coronavirus (COVID-19) remains low for all our trial site locations (Melbourne, Brisbane and Minnesota), however, to protect the safety of our participants, staff and trial facilities, we have introduced some additional screening measures.

     

    IMPORTANT

    It is important that you self-isolate if you have knowingly contracted Coronavirus (COVID-19)

    You must answer truthfully when providing information via our online, print and phone channels. Providing false information would equate to an offence.

     

    Phone screening: Participants will be questioned over the phone to determine if they have any risk factors for Coronavirus (COVID-19) exposure.:

    • Travel to or contact with someone who has travelled overseas or out of state within the last 14 days
    • Have stayed or are currently residing in accommodation with high occupant turnover -  This includes dormitory type accommodation within the last 14 days
    • Had direct contact with anyone known to be infected with Coronavirus (COVID-19), and/or
    • Currently have or have had cold / flu symptoms in the past 14 days.

     

    Anyone who answers ‘yes’ to any of the questions above should not visit the unit. If you already have a screening appointment planned, please call 651-641-2900

    Medical screening (in clinic): The above questions will again be asked when the participant presents for their screening visit and the participant will also have their temperature taken and be requested to wash their hands with hand sanitiser upon presentation. However, we ask that if participants do have any cold or flu like symptoms, they inform the clinic and do not attend their medical screening. We will advise the most appropriate action.

    Outpatient visits (in clinic): Active trial participants attending the site for an inpatient or outpatient visit will be required to undergo the same process as described above. It is important for participant safety that all outpatient visits are attended as scheduled during the trial process. However, we ask that if participants do have any cold or flu like symptoms, they inform the clinic and not attend their medical screening. We will advise the most appropriate action.

    Are clinical trials included under the ‘essential travel’ classification?

    Yes. Clinical trials play an imperative, and essential, role in advancing medicines (including vaccines) for the entire community and therefore meet the essential travel requirements.

    Have social distancing measures been implemented at Nucleus Network sites (Centre for Clinical Studies, Q-Pharm or Prism)?

    Yes. Nucleus Network is strictly to social distancing measures with all Nucleus Network sites meeting the 6 ft per person distancing requirements. To ensure we meet, and surpass, this distance we have implemented an ‘every second bed’ policy, where the clinical beds are a minimum 6 feet apart.

    What if I feel unwell after being admitted for a confinement period for a clinical trial?

    Trial participants who begin to experience side effects, changes in their health or have concerns should always speak with the clinical staff / study doctor as soon as possible. In relation to Coronavirus (COVID-19), any fever, cough or other flu like  symptoms noted should immediately be brought to the attention of clinical staff. We will need to medically assess participants and, if necessary, relocate to a different area for further treatment whilst it is established what the cause is.

    Can I still have visitors during my stay at the facility?

    Visitors are usually permitted during long-stay trial admissions. However, to reduce risk of Coronavirus (COVID-19) transmission we will be restricting visitor access at our facilities until further notice. We apologise for this inconvenience and understand the stress this may cause in some cases. We will work with trial participants to find alternative ways to remain in contact with family and friends.

    With your help, we can make a difference in the containment of COVID-19 as together we work on developing the medicines of tomorrow.

    Useful links:

  • Register with Our Database

    Registration form here.

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies.

    Find the registration form here

     Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

    We will not share or sell this info with any third party.

    Thanks for your interest!

  • BMI Calculator

     BMI stands for "Body Mass Index," and it's a calculation determined by your height and weight. There is almost always a BMI range in Prism's studies. 

    Why does the BMI range exist? To provide an expected norm within which the population of participants will fall.

    Why is there a BMI limit? A participant with a higher BMI may require a greater dose of the study drug and therefore may metabolize the drug differently than a person with a lower BMI.

    Why does the BMI range change from study to study? The range is determined by the study sponsor. The range is based on the type of study, the procedures being done, and the study drug.

     

    Determine your BMI here 

     

     

  • Upcoming Studies

     

     

     Prism has a variety of upcoming studies to participate in: 

    • Inpatient and Outpatient studies for healthy males and females; Age 18-55 years old
    • Liver Impairment 
    • Kidney Impairment 

    To be put on the call list and receive more information, when available, please contact Dayna at daynas@prismresearchinc.com or Lindsay at lindsayd@prismresearchinc.com.

  • Diagnosed with Kidney or Liver Impairment?

     

     

    KIDNEY IMPAIRMENT:

    Schedule a time to talk: https://bit.ly/2UBaoAE

    Prism Research has upcoming studies for individuals diagnosed with kidney impairment. These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of kidney impairment when compared to volunteers with normal kidney function.

     If you or someone you know has been diagnosed with kidney impairment and are interested in being considered for these studies, please contact Lindsay at 651-368-3360 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Please contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

     

     

    LIVER IMPAIRMENT:

    Schedule a time to talk: https://bit.ly/2DFskFj

    Prism Research has upcoming studies for individuals diagnosed with liver impairment. These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

     

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

     

     

     

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must qualify for a study.
    • Subject may not be referred more than one time.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any prior study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Connect With Us on Social Media and with Prism Text

    PRISM TEXT:

    This texting feature will be a convenient way for the Recruitment Department to TEXT you about upcoming studies. 

    You will be receiving text message from us if you are qualified for a study.

    You are considered OPT-IN unless you tell us to remove you (OPT OUT).

    The texting system is through our secure online database and will not compromise  your phone number. 

     

    SOCIAL MEDIA:

    Have you LIKED Prism Clinical Research on Facebook?

    Have you TAGGED Prism Clinical Research on Twitter?

    Have you FOLLOWED Prism Clinical Research on Instagram?

    Have you SEARCHED 651-368-3360 on Whatsapp?

    Have you WRITTEN A REVIEW on Google? 

    Have you WATCHED on YouTube?

     

    Use the links below:↓

    https://www.facebook.com/PrismResearch/

    https://twitter.com/ResearchPrism

    https://www.instagram.com/prismclinical_research/?hl=en

    https://www.youtube.com/channel/UCozYBk43CpVR9LT54BSQg3g/

  • Kidney Impairment: Clinical Research Study 1907

    Renal Impairment Study

    Clinical RESEARCH study: 1907

     

    PRISM RESEARCH

     

    Purpose:

    • To evaluate the safety and tolerability of an investigational drug being developed for  a type of liver disease

     

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages of 18-70 with a BMI between 18-38
    • Must be a nonsmoker
    • Medical conditions and medications must be stable in the opinion of the study doctor.

     

    STUDY DURATION:

    • In Clinic Stay: 11 nights/12 days
    • Return Clinic Visits: 4 including screening
    • Total study duration is up to 49 days

     

    METHOD OF ADMINISTRATION:

    • Oral Dose

     

    STUDY COMPENSATION:

    • Compensation up to $3980.00 for Study Participation Time

     

    RECRUITMENT CONTACT:

  • Liver Impairment: Clinical Research Study 1913

    Liver Impairment Study

    Clinical RESEARCH study: 1913

     

    PRISM RESEARCH

     

    Purpose:

    • To evaluate the safety and tolerability of an investigational drug being developed for treatment of certain types of cancer in healthy volunteers and volunteers who have been diagnosed with different levels of liver impairment.

     

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages of 18-75 with a BMI between 18-40
    • Liver impairment volunteers: must have mild/moderate/severe liver impairment documented by medical history
    • Healthy Match volunteers: must be healthy; not being evaluated or treated for any medical conditions

     

    STUDY DURATION:

    • In Clinic Stay: 9 days/8 nights
    • Return Clinic Visits: 2 including screening
    • Total study duration is up to 43 (including screening)

     

    METHOD OF ADMINISTRATION:

    • Oral Dose

     

    STUDY COMPENSATION:

    • Compensation for Study Participation Time Up To: $2740.00

     

    RECRUITMENT CONTACT:

  • Dialysis: Clinical Research Study 2006

     

    Schedule a phone pre-screen:  https://bit.ly/2MmLL71

     

     

     

    Renal Impairment Study: Part 1

    Clinical RESEARCH study: 2006

     

    PRISM RESEARCH

     

    Purpose:

    • To evaluate the safety and tolerability of a single dose medication that is being developed for the prevention of blood clotting complications in volunteers with end stage renal disease who are on dialysis.

     

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages of 40-80 with a BMI between 18-42
    • Receiving dialysis treatments at least 3 times per week
    • Must not be taking an anticoagulation therapy
    • Medical conditions and medications must be stable in the opinion of the study doctor.
    • Women must be of non-child bearing potential

     

    STUDY DURATION:

    • Screening: 3 Visits will be required for screening
    • In Clinic Stay: 3 nights/4 days
    • Outpatient Visits: 10 visits
    • Total study duration: 192 days

     

    METHOD OF ADMINISTRATION:

    • Intravenously

     

    STUDY COMPENSATION:

    • Part 1 compensation up to $2648.00 for study participation time

     

    RECRUITMENT CONTACT:

    • Jenna at 651-724-0500 or jennal@prismresearchinc.com
  • Kidney Impairment: Clinical Research Study 2009

    Renal Impairment Study

    Clinical RESEARCH study: 2009

     

    PRISM RESEARCH

      

    Purpose:

    •  To evaluate the safety, tolerability and pharmacokinetics of an investigational drug in healthy volunteers and volunteers with different levels of renal impairment.  The investigational drug being developed for the treatment of inflammatory disease.

     

    GENERAL STUDY REQUIREMENTS:

    •  Men and Women, between the ages of 18-75 with a BMI between 17.5 - 40
    •  Medical conditions and medications must be stable in the opinion of the study doctor

     

    STUDY DURATION:

    •  In Clinic Stay: 4 nights/5 days
    •  Return Clinic Visits: 3 (including 2 screening visits)
    •  Total study duration is up to 63 days

     

    METHOD OF ADMINISTRATION:

    •  Oral Dose

     

    STUDY COMPENSATION:

    • Compensation for Study Participation Time Up To: $1,785.00

     

    RECRUITMENT CONTACT:

     

  • HEALTHY: CLINICAL RESEARCH STUDY 2020 SAD

    PRISM RESEARCH

    Cohorts 1-3 and 5-7

    PURPOSE:

    • Phase 1 study to determine the safety and tolerability of a single dose of HU6 in healthy volunteers. HU6 is being developed to treat nonalcoholic steatohepatitis (NASH).

     

    GENERAL STUDY REQUIREMENTS Cohort 1-3, 6 and 7:

    • Males and Females between the ages 18-45 years old

    • Must be healthy and not taking any medications (birth control is acceptable)

    • Must have a BMI of 18.0 - 30.0

    • Must be a Non-smoker

    • Must not be claustrophobic or have intolerance of closed or small spaces

     

    COHORT 5

    • Must have BMI > 30.0 kg/m2, waist circumference > 41 inches

    • Medications will be reviewed on a case by case basis

     

    STUDY DURATION:

    • Clinic Visits: 1 Screening

    • In clinic stay: 3 consecutive nights/ 4 days

    • Follow Up: 1 in person follow up Day 5

    • Total Study Duration: 33 days (including screening window)

     

    STUDY DATES:

    • Multiple Admits:

    8/24/2020, 8/26/2020, or 09/08/2020

     

    METHOD OF ADMINISTRATION:

    • Oral capsule

     

    STUDY COMPENSATION:

    Compensation for study participation may be provided for time and travel up to $1,100.00

     

    RECRUITMENT CONTACT:

    • Dayna 651-724-5047 or daynas@prismresearchinc.com

    Lindsay 651-368-3360 or lindsayd@prismresearchinc.com

    • Schedule a call: https://calendly.com/prism-recruitment/2020-phone-pre-screen

Where hope, science & understanding meet.

From the aspirin on the shelves of your local drugstore, to the insulin prescribed by a doctor, to the pacemaker keeping someone’s heart on track – all have been subject to clinical trials, and integral part of the Food and Drug Administration (FDA) approval process.

A critical step in an important process

Drugs and medical devices undergo years of laboratory testing before they reach the clinical trial phase. Researchers must acquire approval from the FDA for approval to continue research and testing in humans. Clinical trials are essential to measure the efficacy and safety of drugs before they are available for widespread use.

Changing lives, every day.

The impact of clinical trials are seen in our everyday lives, in the confidence with which we can take over-the-counter drugs – or in the life-saving benefits of a breakthrough medication for a victim of Leukemia.

Public Health and Safety

Prior to the development of the FDA’s rigorous and highly regulated method, consumers had to rely upon the anecdotal observation of physicians or spurious claims of pharmacists. In 1906, in order to protect public health and safety, the fledgling FDA passed the first regulatory drug act – the Pure Food and Drug Act.

In 1938, the enactment of the U.S. Food, Drug, and Cosmetic Act subjected new drugs to pre-market safety evaluation for the first time, thus enabling FDA regulators to review both pre-clinical and clinical test results, giving them the authority to block the marketing of a new drug formally or delay it by requiring additional data.

Alongside the evolving standards of drug regulations, closer regulation of the clinical trial process. The resulting process today is designed to protect the safety of study participants, promote the development of lifesaving drugs, and keep public health and safety at the center of medical advancement. In the century since the first drug act, the research and medical community in cooperation with the FDA, have developed the foremost institutional authority for conducting and evaluating controlled clinical drug trials.

Doing the right thing

Know that you’ve done your part to help make important medications available to those who need them. If you have a friend or family member who relies on a medication to treat a chronic disease or illness, they have benefited from the work of a clinical trial, and a volunteer like you who gave their time and effort to aid in the approval process.

Fair compensation for your time

You’ll be compensated based on the time you spend as a study participant.

Medical exam & monitoring

As a study participant, you’ll likely receive a full medical examination and testing for a variety of conditions. In some cases volunteers might have access to treatments or medicines before they are available to the general population.

Changing lives, advancing science, furthering the reach of medicine.

Prism Clinical Research provides, FDA approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians as well as other researchers across Minnesota.

Icon 05

At Prism, we are committed to the advancement of medical knowledge and the health of our community. We have been conducting Phase I clinical trials since 2005, helping many important drugs reach FDA approval. Prism is a locally owned and operated, independent facility in the heart of the Minneapolis/St. Paul metropolitan area. 

Whether you are here because you are interested in participating in a clinical trial, or you’re searching for a trusted partner to conduct a study on your behalf, our hope is that you find the information you need and the confidence to take the next step. 

With your help, we can make a difference.


Learn what Prism Volunteers are saying:

Volunteer Large 13

"I am VERY pleased with Prism Research. I enjoy the studies and the staff is always friendly and they all make you feel as comfortable as possible. The study compensation program is very good as well! Thank you."

  • Capture

    “Awesome as always!  The staff is great and they are very professional.”

  • Volunteers 05

    “Really a great experience!”

  • Volunteers 06

    “Staff was courteous and well informed of the nature of the study and all of the requirements that went with it.”

  • Volunteers 07

     “Overall my experiences at Prism have been very positive and directly linked to the Staff - their demeanor, humor and professional approach.”


Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel